Craig M. Goodwin

1.6k citations

17 papers · 334 indexed · h-index 7

Toxicology
Oncology
- Pancreatic and Hepatic Oncology Research 3
- Peptidase Inhibition and Analysis 2
Molecular Biology
- Protein Degradation and Inhibitors 4
- Cell death mechanisms and regulation 3
- PI3K/AKT/mTOR signaling in cancer 2
- Ubiquitin and proteasome pathways 2
Organic Chemistry
Computational Theory and Mathematics top 10%
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 2
Cancer Research
- Cancer Genomics and Diagnostics 2

Co-authors: Edward T. Olejniczak Olivia W. Rossanese Stephen W. FesikBin ZhaoJohannes Belmar Zhiguo Bian Taekyu Lee Anders Friberg
Cited by: Toxicology Oncology Molecular Biology
Journals: Cancer Research (5 papers)Clinical Cancer Research (1 paper)Journal of Colloid and Interface Science (1 paper)
Partner nations: United States Iceland Taiwan

In The Last Decade

Craig M. Goodwin

17 papers receiving 321 citations

Peers

Countries citing papers authored by Craig M. Goodwin

Since Specialization

Citations

This map shows the geographic impact of Craig M. Goodwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig M. Goodwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig M. Goodwin more than expected).

Fields of papers citing papers by Craig M. Goodwin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig M. Goodwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig M. Goodwin. The network helps show where Craig M. Goodwin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Craig M. Goodwin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Craig M. Goodwin Line = papers co-authored together Craig M. Goodwin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	RHOA^L57Vdrives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling Science Signaling ·Antje Schaefer,Richard G. Hodge,Haisheng Zhang,G. Aaron Hobbs,Julien Dilly,Minh V. Huynh,Craig M. Goodwin,Feifei Zhang,J. Nathaniel Diehl,Mariaelena Pierobon,Elisa Baldelli,Sehrish Javaid,K M Guthrie,Naim U. Rashid,Emanuel F. Petricoin,Adrienne D. Cox,William C. Hahn,Andrew J. Aguirre,Adam J Bass,Channing J. Der	2023	5
2	Abstract 1075: Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer Cancer Research ·Andrew M. Waters,Wen-Hsuan Chang,Clint A. Stalnecker,Cole Edwards,Runying Yang,Craig M. Goodwin,Adrienne D. Cox,Channing J. Der	2023	1
3	VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer Genes & Cancer ·Ye S. Lee,Jennifer E. Klomp,Clint A. Stalnecker,Craig M. Goodwin,Yanzhe Gao,Gaith N. Droby,Cyrus Vaziri,Kirsten L. Bryant,Channing J. Der,Adrienne D. Cox	2023	5
4	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma Molecular Cancer Therapeutics ·Sehrish Javaid,Antje Schaefer,Craig M. Goodwin,Victoria V. Nguyen,Frances L. Massey,Mariaelena Pierobon,Da'Jhnae Gambrell-Sanders,Andrew M. Waters,Kathryn N. Lambert,J. Nathaniel Diehl,G. Aaron Hobbs,Kris C. Wood,Emanuel F. Petricoin,Channing J. Der,Adrienne D. Cox	2022	10
5	Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer Advances in cancer research ·J. Nathaniel Diehl,Priya S. Hibshman,Irem Ozkan‐Dagliyan,Craig M. Goodwin,Sarah V. Howard,Adrienne D. Cox,Channing J. Der	2022	12
6	Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen Molecular Oncology ·Anna Barkovskaya,Craig M. Goodwin,Kotryna Seip,Bylgja Hilmarsdóttir,Solveig Pettersen,Clint A. Stalnecker,Olav Engebraaten,Eiríkur Briem,Channing J. Der,Siver Andreas Moestue,Þórarinn Guðjónsson,Gunhild M. Mælandsmo,Lina Prasmickaite	2021	4
7	Abstract LB251: Vertical inhibition of the RAF MEK ERK cascade induces myogenic differentiation, apoptosis and tumor regression in H/NRAS Q61X mutant rhabdomyosarcoma Cancer Research ·Natália Garcia,Vanessa Del-Pozo,Marielle E. Yohe,Craig M. Goodwin,Terry J. Shackleford,Long Wang,Kunal Baxi,Yidong Chen,Myron S. Ignatius,Kris C. Wood,Peter Houghton,Angelina V. Vaseva	2021	1
8	Abstract B15: CRISPR/Cas9 genetic screen identifies novel therapeutic strategies for treating HRAS mutant HNSCC with farnesyltransferase inhibitors (FTIs) Clinical Cancer Research ·Sehrish-Javaid,Craig M. Goodwin,Kirsten L. Bryant,Samuel D. George,Victoria V. Nguyen,Kathryn N. Lambert,Andrew M. Waters,Channing J. Der,Adrienne D. Cox	2020	1
9	Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer Cancer Research ·Craig M. Goodwin,Sehrish Javaid,Andrew M. Waters,Bjoern Papke,Runying Yang,Mariaelena Pierobon,Daniel M. Freed,Patrick J. Roberts,Adrienne D. Cox,Kris C. Wood,Emanuel F. Petricoin,Autumn J. McRee,Channing J. Der	2019	1
10	Abstract SY20-02: Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer Cancer Research ·Adrienne D. Cox,Craig M. Goodwin,Kirsten L. Bryant,Irem Dagliyan,Samuel D. George,Kelly E. Lucas,Prson Gautam,Krister Wennerberg,Channing J. Der	2018	1
11	Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods Journal of Medicinal Chemistry ·Nicholas F. Pelz,Zhiguo Bian,Bin Zhao,Subrata Shaw,James C. Tarr,Johannes Belmar,Claire Gregg,DeMarco V. Camper,Craig M. Goodwin,Allison L. Arnold,John Sensintaffar,Anders Friberg,Olivia W. Rossanese,Taekyu Lee,Edward T. Olejniczak,Stephen W. Fesik	2016	108
12	Abstract 3727: Small molecule Mcl-1 inhibitors induce apoptosis and death in multiple cancer subtypes in vitro Cancer Research ·John Sensintaffar,Allison L. Arnold,Craig M. Goodwin,Leah J. Hogdal,Subrata Shaw,James C. Tarr,Taekyu Lee,Edward T. Olejniczak,Stephen W. Fesik	2016	1
13	Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer Cell Death and Differentiation ·Craig M. Goodwin,Olivia W. Rossanese,Edward T. Olejniczak,Stephen W. Fesik	2015	87
14	Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design Journal of Medicinal Chemistry ·Jason P. Burke,Zhiguo Bian,Subrata Shaw,Bin Zhao,Craig M. Goodwin,Johannes Belmar,Carrie F. Browning,Dominico Vigil,Anders Friberg,DeMarco V. Camper,Olivia W. Rossanese,Taekyu Lee,Edward T. Olejniczak,Stephen W. Fesik	2015	74
15	Potential of Chromium(III) Picolinate for Reproductive or Developmental Toxicity Following Exposure of Male CD-1 Mice Prior to Mating Biological Trace Element Research ·DeAna McAdory,Nicholas R. Rhodes,Felicia Briggins,Melissa M. Bailey,Kristin R. Di Bona,Craig M. Goodwin,John B. Vincent,Jane F. Rasco	2011	13
16	Advanced cable diagnostics - evaluation, selection, application and experience on medium voltage shielded power cables at a petrochemical facility Dan W. Eaton,Craig S. Schiro,Terry Perilloux,Craig M. Goodwin	2011	6
17	Binding energies for alkane molecules on a carbon surface from gas–solid chromatography and molecular mechanics Journal of Colloid and Interface Science ·Thomas R. Rybolt,Christina E. Wells,Howard E. Thomas,Craig M. Goodwin,Jennifer L. Blakely,James D. Turner	2008	4

About Craig M. Goodwin

Craig M. Goodwin is a scholar working on Oncology, Hematology and Molecular Biology, having authored 17 papers that have together received 334 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Cell death mechanisms and regulation (3 papers), Advanced Breast Cancer Therapies (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Peptidase Inhibition and Analysis (2 papers), Ubiquitin and proteasome pathways (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Toxicology (13 citations), Oncology (101 citations) and Molecular Biology (237 citations). Craig M. Goodwin has collaborated with scholars based in United States, Iceland and Taiwan. Frequent co-authors include Edward T. Olejniczak, Olivia W. Rossanese, Stephen W. Fesik, Bin Zhao, Johannes Belmar, Zhiguo Bian, Taekyu Lee, Anders Friberg, DeMarco V. Camper and Subrata Shaw. Their work appears in journals such as Cancer Research, Clinical Cancer Research and Journal of Colloid and Interface Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact